Exciting developments are underway at our production site in Chartres, France! This week, members of our leadership team and board visited the site to see how we’re investing in and significantly expanding our facilities to meet the needs of millions of people living with diabetes, obesity, and other serious chronic diseases. By 2028, we aim to welcome 500 new colleagues, and increase our capacity to serve many more patients. A special thanks to our 1700 dedicated colleagues at Chartres, who produce life-saving treatments.
Novo Nordisk
Produktion af lægemidler
Driving change to defeat serious chronic diseases, built upon our heritage in diabetes.
Om os
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
- Websted
-
https://www.novonordisk.com
Eksternt link til Novo Nordisk
- Branche
- Produktion af lægemidler
- Virksomhedsstørrelse
- Over 10.001 medarbejdere
- Hovedkvarter
- Bagsværd
- Type
- Aktieselskab
- Grundlagt
- 1923
- Specialer
- Pharmaceuticals, Insulin, obesity, Rare Diseases og Diabetes
Beliggenheder
Medarbejdere hos Novo Nordisk
-
Thomas Røygaard
PMO | Digital Transformation | Leading Program, Project and Portfolio Management | Governance | Change Management
-
Naras Eechambadi
Global Leader in Data & AI | C-Suite Executive | Board Director | DataIQ Top10 | Executive Coach
-
Sören Meelby
Strategic Alliance Evangelist | Cultivating Partnerships for Collective Impact & Social Good
-
Henrik Vestergaard
Opdateringer
-
Did you know? MASH, or metabolic dysfunction-associated steatohepatitis, is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not managed properly. It is often described as a ‘silent disease’ due to the lack of specific symptoms in the early stages of the disease, which often contributes to a delay in diagnosis. 13 June is Global #FattyLiverDay 🌎 Learn more about living with the condition and the impact of a late diagnosis from Tania. Watch Tania’s story here: https://lnkd.in/dAw55qZV At Novo Nordisk, we are committed to continuing our research with the ambition of developing innovations that can help address the underlying cause of this disease. We hope to double diagnostic rates for people living with moderate to advanced MASH by 2027 💙
-
The count down is on and we're looking forward to #ISTH2024 in Bangkok! Follow along online between 22 - 26 June as we address the unmet needs in haemophilia, and raise awareness of rare diseases 👇 https://bit.ly/4bYBdoI #ChangingHaemophilia
Discover more at Novo Nordisk CongressHub
-
Have you ever heard of the chronic disease, MASH? It is a progressive, chronic, metabolic liver disease that impacts more than 250 million people globally. It is often described as a ‘silent disease’ due to lack of symptoms and lack of awareness – all contributing to a delay in diagnosis. Thousands of liver specialists are at the #EASLCongress2024 in Milan to highlight new developments in MASH. We are looking forward to engaging peers from around the world, as we advance the science to help people living with this progressive disease. To learn more about MASH, click here: https://lnkd.in/dzRkrH8N #EASLCongress2024 #drivingchange #ActOnMASH
-
There is something powerful about raising a flag and seeing it fly strong and proud 🏳️🌈 That’s certainly what we felt as the Progressive Pride Flag was raised once again, at many of our sites and offices around the world to start off this year’s #PrideMonth. Our ambition is to cultivate an inclusive environment by tailoring policies and initiatives that specifically support the needs of our LGBTQ+ colleagues, and focus on the allyship and actions that drive everyday LGBTQ+ inclusion. Curious to know more? Read more here: https://lnkd.in/dfT5m4AS
-
+ 1
-
This Pride Month, we proudly announce an extension of our parental leave offering. From January 2025, we will offer a minimum of 14 weeks paid leave to all non-birthing parents globally, regardless of gender 🏳️🌈 When we ask people to come to work as their whole selves, we have a responsibility to support them – in Novo Nordisk and at home ❤️ Hear our colleague Ersoy's perspective on the policy and learn more here: https://lnkd.in/dfT5m4AS Happy #PrideMonth!
-
From groundbreaking research to leaders driving change, exceptional women have left their mark on our history through their ambitions and dedication. Which changemaker inspires you the most? Share in the comments 👇 #DrivingChange #WomenInHistory
-
It's International #ClinicalTrialsDay! Thank you to the thousands of participants and to all colleagues for driving scientific innovation and improved patient care. #DrivingChange #Innovation #ICTD2024
-
What a fantastic #ECO2024, exploring the latest advancements in obesity care. We look forward to seeing you again next year👋 #DrivingChange Catch up on all the highlights from this year's ECO and the latest in obesity related innovations over at Novo Nordisk CongressHub now 👇 https://lnkd.in/d7ANxye4 #Obesity #Innovation
-
We’re student favourites again! This time we’ve not only been ranked the #1 Most Attractive Employer in Denmark 2024 by students within Engineering/Natural Science, but also within Business and IT! Thank you to all the students who voted for us, it means the world to us to know that future talent sees Novo Nordisk as an attractive employer. We’re always looking to hire talented students, if you are interested in working at Novo Nordisk, explore our early talent career opportunities here: https://brnw.ch/21wJNoD
Tilsvarende sider
Aktie
NVO
NYSE
20 minutters forsinkelse
142,56 US$
0,07 (0,049 %)
- Åbningspris
- 142,21
- Lavpunkt
- 141,89
- Højdepunkt
- 143,18
Data fra Refinitiv
Få flere oplysninger påFinansiering
Seneste runde
Post IPO-egenkapital22.000.000,00 US$